Innovent dosed the primary affected person in a part 3 trial of IBI354, an anti-HER2 antibody-drug conjugate for platinum-resistant ovarian most cancers.The primary...
Panelists focus on how a number of myeloma sufferers typically navigate by quite a few therapy regimens over their illness course, incessantly biking...
Panelists talk about how the present remedy panorama for sufferers with late-line relapsed/refractory a number of myeloma (RRMM) entails novel approaches comparable to...
EVM14, an mRNA most cancers vaccine, gained FDA clearance for scientific trials, advancing Everest Medicines’ efforts in oncology drug growth.EVM14, a tumor-associated antigen...
